However, in prostate cancer, upregulation of the antioxidative stress factor SRXN1 leads to radiotherapy tolerance, which can potentially be used to predict the prognosis of prostate cancer patients after radiotherapy. Here, SRXN1 is linked to prostate carcinoma.